ABN AMRO signs diamond deal

ABN AMRO Bank has signed a sponsorship agreement with the PolishedPrices Index, the financial services company said Wednesday.

By AVI KRAWITZ
August 23, 2006 08:33

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

ABN AMRO Bank has signed a sponsorship agreement with the PolishedPrices Index, the financial services company said Wednesday. The agreement will see the combination of the PolishedPrices' benchmark index with ABN AMRO's derivative trading expertise and presence in the global financial markets identify opportunities for investors and diamond corporations seeking instruments for production and trading hedging, ABN AMRO said. The index was launched five years ago by PolishedPrices.com, a specialist data and information services company, and tracks polished diamond prices globally, providing price movements, trading volumes and volatility in diamonds between 0.3 carats and 3 carats.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS